• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Obsidian Therapeutics (OBX) Reached A Trial Milestone, Does The Valuation Already Look Full?

    Simply Wall St·08/11/2026 01:32:58
    Listen to the news

    Why Obsidian Therapeutics Stock Is Back in Focus After New Trial Milestone

    Obsidian Therapeutics (OBX) is drawing fresh attention after enrolling the first patient in a registration enabling cohort of its Phase 1/2 Agni-01 trial for amsoki-cel in advanced melanoma.

    See our latest analysis for Obsidian Therapeutics.

    The trial milestone comes after a sharp rebound in Obsidian Therapeutics’ share price, with a 1 day share price return of 27.27% and a year to date share price return of 435.22%. However, the 3 year total shareholder return has fallen 59.06% and the 5 year total shareholder return has fallen 98.51%.

    If this kind of move has your attention, it can be useful to see what else is happening in healthcare focused AI. Take a look at 43 healthcare AI stocks

    Bulls point to Obsidian Therapeutics’ trial progress and index inclusion. Bears highlight years of weak long term returns and ongoing losses. Which side does the current US$1.19b market value and US$35 share price support next?

    Preferred Price-To-Book Multiple Of -5.5x: Is It Justified For Obsidian Therapeutics?

    With Obsidian Therapeutics carrying negative equity and a P/B ratio of -5.5x, the usual multiple lens does not give a clear valuation signal. That is very different to the US Biotechs industry average P/B of 2.5x, so investors relying purely on book value comparisons may struggle to frame the current $35 share price.

    The P/B ratio typically compares a company’s market value to its net assets. It is often used for mature or asset heavy businesses. In Obsidian Therapeutics’ case, negative equity means total liabilities are higher than recorded assets. That breaks the usual link between book value and potential liquidation or replacement value.

    For a clinical stage biotech like Obsidian Therapeutics, most of the potential value sits in trial assets and intellectual property, not in current accounting equity. Negative equity can stem from accumulated losses as the company spends on research and development ahead of any meaningful revenue. The statement that Obsidian Therapeutics makes less than $1m in revenue and reported a loss of $95.254m underlines this early stage profile.

    Given that backdrop, a traditional multiple comparison to the US Biotechs industry is hard to interpret. The reported P/B of -5.5x versus an industry average of 2.5x simply highlights how different Obsidian Therapeutics’ balance sheet structure is from peers that have positive equity. In practice, many investors in this part of the sector pay closer attention to trial progress, cash runway and the path to potential profitability rather than book based ratios.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Preferred multiple of price-to-book of -5.5x (ABOUT RIGHT)

    However, Obsidian Therapeutics still faces clinical trial uncertainty and ongoing losses of $95.254m, which could challenge sentiment if trial timelines or funding needs change.

    Find out about the key risks to this Obsidian Therapeutics narrative.

    Next Steps

    Given the mixed picture around Obsidian Therapeutics, it helps to look past the headline moves and review the underlying data yourself. If you want to stress test your view against the key risk factors that investors are watching right now, start with these 6 important warning signs.

    Looking for more investment ideas beyond Obsidian Therapeutics?

    If Obsidian Therapeutics has sharpened your interest, broaden your watchlist with a few focused stock ideas that match different risk profiles and income goals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.